Abstract
Rationale
Antidepressants preferentially facilitating serotonin seem to be particularly effective for treating the anxiety and aggressive component of the depressive syndrome, whereas those with a noradrenergic profile seem to be more effective in reducing psychomotor retardation, although their overall antidepressant effects are about the same. However, the mechanism of this difference remains unknown.
Objectives
To investigate the neural substrate for the different therapeutic efficacies of fluoxetine and reboxetine, we examined the regional Fos immunoreactivity (Fos-ir) induced by the two agents.
Methods
Male Wistar rats (290–330 g) were given a subcutaneous injection of fluoxetine (5 or 10 mg/kg), reboxetine (5 or 10 mg/kg) or saline. Two hours later, rats were perfused through the ascending aorta and their brains were processed for Fos immunohistochemistry. Fos-ir was quantified by counting the number of Fos-ir-positive nuclei in six areas of the forebrain.
Results
The shell of the nucleus accumbens was the only region in which both fluoxetine and reboxetine equally increased Fos-ir expression. Fluoxetine particularly induced Fos-ir in the central nucleus of the amygdala. In contrast, reboxetine induced Fos-ir in the cingulate cortex area 3 and the lateral orbital cortex.
Conclusions
These results suggest that the shell region may be one possible target for the antidepressant effects of fluoxetine and reboxetine. Furthermore, the difference in their clinical effects may depend on their different target sites of action.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alheid GF, Heimer L (1996) Theories of basal forebrain organization and the “emotional motor system”. Prog Brain Res 107:461–484
Beck CH (1995) Acute treatment with antidepressant drugs selectively increases the expression of c-fos in the rat brain. J Psychiatr Neurosci 20:25–32
Belzung C, Le Guisquet AM, Barreau S, Calatayud F (2001) An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice. Behav Pharmacol 12:151–162
Berridge CW, Stratford TL, Foote SL, Kelley AE (1997) Distribution of dopamine beta-hydroxylase-like immunoreactive fibers within the shell subregion of the nucleus accumbens. Synapse 27:230–241
Biederman J, Spencer T (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46:1234–1242
Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS (2002) Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51:273–279
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711
Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067–1070
Catalano G, Hakala SM, Catalano MC (2000) Sertraline-induced panic attacks. Clin Neuropharmacol 23:164–168
Cryan JF, Page ME, Lucki I (2002) Noradrenergic lesions differentially alter the antidepressant-like effects of reboxetine in a modified forced swim test. Eur J Pharmacol 436:197–205
Delfs JM, Zhu Y, Druhan JP, Aston-Jones GS (1998) Origin of noradrenergic afferents to the shell subregion of the nucleus accumbens: anterograde and retrograde tract-tracing studies in the rat. Brain Res 806:127–140
Dragunow M, Faull R (1989) The use of c-fos as a metabolic marker in neuronal pathway tracing. J Neurosci Methods 29:261–265
Drevets WC (2000) Neuroimaging studies of mood disorders. Biol Psychiatry 48:813–829
Dubini A, Bosc M, Polin V (1997) Do noradrenaline and serotonin differentially affect social motivation and behaviour? Eur Neuropsychopharmacol 7:S49–S55; discussion S71–S73
Eriksson E (2000) Antidepressant drugs: does it matter if they inhibit the reuptake of noradrenaline or serotonin? Acta Psychiatr Scand Suppl 402:12–17
Eriksson E, Hedberg MA, Andersch B, Sundblad C (1995) The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 12:167–176
Faw B (2003) Pre-frontal executive committee for perception, working memory, attention, long-term memory, motor control, and thinking: a tutorial review. Conscious Cognit 12:83–139
Ferguson JM, Wesnes KA, Schwartz GE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18:9–14
George MS, Ketter TA, Post RM (1993) SPECT and PET imaging in mood disorders. J Clin Psychiatry 54:6–13
Gresch PJ, Sved AF, Zigmond MJ, Finlay JM (1995) Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65:111–116
Hamamura T, Lee Y, Ohashi K, Fujiwara Y, Miki M, Suzuki H, Kuroda S (2000) A low dose of lithium chloride selectively induces Fos protein in the central nucleus of the amygdala of rat brain. Prog Neuropsychopharmacol Biol Psychiatry 24:285–294
Jongsma ME, Sebens JB, Bosker FJ, Korf J (2002) Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brain. Eur J Pharmacol 455:109–115
Kasper S (1999) From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol 14:S27–S31
Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7:541–547
Massana J, Moller HJ, Burrows GD, Montenegro RM (1999) Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 14:73–80
Modigh K, Westberg P, Eriksson E (1992) Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 12:251–261
Moorman JM, Leslie RA (1996) P-Chloroamphetamine induces c-fos in rat brain: a study of serotonin2A/2C receptor function. Neuroscience 72:129–139
Moorman JM, Jackson A, Grahame-Smith DG, Leslie RA (1995) Induction of c-fos in rat forebrain by pharmacological manipulation of 5-hydroxytryptamine levels. Neuroscience 68:1089–1096
Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT (2002) Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22:389–395
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic, Sydney
Pelosi L, Slade T, Blumhardt LD, Sharma VK (2000) Working memory dysfunction in major depression: an event-related potential study. Clin Neurophysiol 111:1531–1543
Rolls ET (2000) The orbitofrontal cortex and reward. Cereb Cortex 10:284–294
Rose JE, Woolsey CN (1948) The orbitofrontal cortex and its connections with the mediodorsal nucleus in rabbit, sheep, and cat. Res Publ-Assoc Nerv Ment Dis 27:210–232
Rouillard C, Bovetto S, Gervais J, Richard D (1996) Fenfluramine-induced activation of the immediate-early gene c-fos in the striatum: possible interaction between serotonin and dopamine. Brain Res Mol Brain Res 37:105–115
Sagar SM, Sharp FR, Curran T (1988) Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240:1328–1331
Salamone JD, Cousins MS, Snyder BJ (1997) Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neurosci Biobehav Rev 21:341–359
Salchner P, Singewald N (2002) Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology 43:1238–1248
Sasson Y, Iancu I, Fux M, Taub M, Dannon PN, Zohar J (1999) A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 9:191–196
Schoenbaum G, Setlow B (2001) Integrating orbitofrontal cortex into prefrontal theory: common processing themes across species and subdivisions. Learn Mem 8:134–147
Shu SY, Ju G, Fan LZ (1988) The glucose oxidase–DAB–nickel method in peroxidase histochemistry of the nervous system. Neurosci Lett 85:169–171
Singewald N, Salchner P, Sharp T (2003) Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biol Psychiatry 53 275–283
Stephenson CP, Hunt GE, Topple AN, McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine “ecstasy”-induced c-fos expression in rat brain. Neuroscience 92:1011–1023
Stone EA, Zhang Y, John SM, Bing G (1991) c-Fos response to administration of catecholamines into brain by microdialysis. Neurosci Lett 133:33–35
Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004) Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology 171:306–321
Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L (1980) Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Arch Gen Psychiatry 37:1281–1285
Williams RA, Hagerty BM, Cimprich B, Therrien B, Bay E, Oe H (2000) Changes in directed attention and short-term memory in depression. J Psychiatr Res 34:227–238
Acknowledgements
This study was supported by research grants from the Zikei Institute of Psychiatry (Okayama, Japan).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Miyata, S., Hamamura, T., Lee, Y. et al. Contrasting Fos expression induced by acute reboxetine and fluoxetine in the rat forebrain: neuroanatomical substrates for the antidepressant effect. Psychopharmacology 177, 289–295 (2005). https://doi.org/10.1007/s00213-004-2072-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-2072-7